MED Increases Humana (HUM) Price Target to $373.00

Share on StockTwits

Humana (NYSE:HUM) had its price objective lifted by research analysts at MED from $350.00 to $373.00 in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage presently has an “outperform” rating on the insurance provider’s stock. MED’s price objective suggests a potential upside of 10.05% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Piper Jaffray Companies raised their price objective on shares of Humana from $355.00 to $380.00 and gave the stock an “overweight” rating in a research note on Friday, August 24th. Argus raised their price objective on shares of Humana to $375.00 and gave the stock a “buy” rating in a research note on Tuesday, September 4th. Jefferies Financial Group raised their price objective on shares of Humana from $356.00 to $372.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, Morgan Stanley assumed coverage on shares of Humana in a research note on Thursday, July 12th. They issued an “overweight” rating and a $362.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Humana currently has an average rating of “Buy” and a consensus price target of $352.30.

NYSE HUM traded down $0.64 during trading on Thursday, hitting $338.95. The stock had a trading volume of 780,088 shares, compared to its average volume of 655,197. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.43. The company has a market cap of $48.77 billion, a P/E ratio of 25.36, a PEG ratio of 1.73 and a beta of 1.03. Humana has a one year low of $231.90 and a one year high of $355.88.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.29 by $0.29. The business had revenue of $14.21 billion during the quarter, compared to the consensus estimate of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.36%. During the same quarter last year, the firm earned $3.39 earnings per share. As a group, equities research analysts expect that Humana will post 14.44 EPS for the current year.

In related news, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $328.66, for a total value of $5,915,880.00. Following the completion of the transaction, the chief executive officer now owns 71,085 shares of the company’s stock, valued at $23,362,796.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the business’s stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the completion of the transaction, the insider now directly owns 14,289 shares of the company’s stock, valued at approximately $4,715,370. The disclosure for this sale can be found here. Insiders own 0.60% of the company’s stock.

A number of large investors have recently modified their holdings of HUM. FMR LLC raised its stake in Humana by 12.7% in the second quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock worth $3,634,811,000 after buying an additional 1,374,030 shares in the last quarter. Glenmede Trust Co. NA raised its stake in Humana by 153.7% in the second quarter. Glenmede Trust Co. NA now owns 500,266 shares of the insurance provider’s stock worth $148,895,000 after buying an additional 303,080 shares in the last quarter. Ffcm LLC raised its stake in Humana by 5,891.4% in the third quarter. Ffcm LLC now owns 288,544 shares of the insurance provider’s stock worth $14,968,000 after buying an additional 283,728 shares in the last quarter. Unigestion Holding SA bought a new position in Humana in the second quarter worth approximately $79,340,000. Finally, LFA Lugano Financial Advisors SA bought a new position in Humana in the second quarter worth approximately $204,000. 92.62% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

See Also: What is a conference call?

The Fly

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply